Abstract-Thiazide diuretics, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers all cause reactive rises in plasma renin activity. We hypothesized that renin inhibition with aliskiren would prevent this reactive rise and also enhance blood pressure lowering. In 3 open-label studies in which blood pressure was assessed with ambulatory measurement, aliskiren was administered to patients with mild-to-moderate hypertension in combination with hydrochlorothiazide (nϭ23), ramipril (nϭ21), or irbesartan (nϭ23). In the diuretic combination study, . Aliskiren (150 mg) alone significantly inhibited plasma renin activity by 65% (PϽ0.0001). Ramipril and irbesartan monotherapy caused 90% and 175% increases in plasma renin activity, respectively. By contrast, when aliskiren was coadministered with hydrochlorothiazide, ramipril, or irbesartan, plasma renin activity did not increase but remained similar to baseline levels or was decreased ( Key Words: aliskiren Ⅲ ambulatory blood pressure measurement Ⅲ combination therapy Ⅲ hypertension Ⅲ plasma renin activity Ⅲ renin inhibitor Ⅲ renin-angiotensin-aldosterone system A ctivation of the renin-angiotensin (Ang)-aldosterone system (RAAS) plays an important role in the development of hypertension and end-organ damage. 1 Indeed, pretreatment plasma renin activity (PRA) has been shown to be a risk factor for myocardial infarction in hypertensive patients. 2,3 RAAS suppression is, therefore, an important goal of antihypertensive therapy, and RAAS inhibitors, such as Ang-converting enzyme (ACE) inhibitors and Ang receptor blockers (ARBs), have proven to be highly successful treatments for hypertension, heart failure, and related cardiovascular disorders. 4 However, optimized RAAS suppression is difficult to achieve with currently available antihypertensive agents, because ACE inhibitors, ARBs, and diuretics all activate compen-
A ctivation of the renin-angiotensin (Ang)-aldosterone system (RAAS) plays an important role in the development of hypertension and end-organ damage. 1 Indeed, pretreatment plasma renin activity (PRA) has been shown to be a risk factor for myocardial infarction in hypertensive patients. 2, 3 RAAS suppression is, therefore, an important goal of antihypertensive therapy, and RAAS inhibitors, such as Ang-converting enzyme (ACE) inhibitors and Ang receptor blockers (ARBs), have proven to be highly successful treatments for hypertension, heart failure, and related cardiovascular disorders. 4 However, optimized RAAS suppression is difficult to achieve with currently available antihypertensive agents, because ACE inhibitors, ARBs, and diuretics all activate compen-satory feedback mechanisms that result in renin release and increased PRA. 5, 6 ACE inhibitors cause an increase in PRA and Ang I, which is then available for conversion to Ang II by both remaining unblocked ACE and by ACE-independent pathways, 7 whereas ARBs and diuretics increase PRA, Ang I, and Ang II. By contrast, renin inhibitors neutralize any compensatory increase in PRA and prevent the formation of both Ang I and Ang II. 8 Although a variety of potential renin inhibitors have been developed, their low potency and/or poor pharmacokinetic profiles prevented these compounds from being developed for clinical use. 9, 10 Aliskiren, the first in a new class of orally effective renin inhibitors for the treatment of hypertension, is a potent and specific inhibitor of human renin in vitro with an IC 50 in the low nanomolar range. [11] [12] [13] Once-daily oral doses of aliskiren of Յ640 mg caused dose-dependent and sustained RAAS inhibition with excellent tolerability in healthy volunteers, 14 whereas recent studies in patients with mild-tomoderate hypertension have shown that aliskiren provides antihypertensive efficacy and safety at least equivalent to the ARBs losartan and irbesartan. 15, 16 The aim of the 3 open-label studies presented in this article was to investigate the antihypertensive efficacy of aliskiren, when combined with a diuretic (hydrochlorothiazide [HCTZ]), an ACE inhibitor (ramipril), or an ARB (irbesartan) in patients with mild-to-moderate hypertension. Ambulatory blood pressure measurement (ABPM) was used to assess the effects of aliskiren throughout the 24-hour dosing interval, and the effects of aliskiren on PRA were also investigated to examine whether RAAS suppression was optimized in combination with agents known to stimulate PRA.
Methods

Participants
Men and women, aged 18 to 80 years, with off-treatment average daytime systolic ABPM Ն140 and Յ180 mm Hg, who were otherwise in good health, were eligible for entry into the studies. Patients had to be previously untreated or to be receiving only antihypertensive monotherapy; women had to be postmenopausal, surgically sterile, or using appropriate contraception. Patients were ineligible for inclusion if current antihypertensive medications could not be withdrawn or if they had secondary hypertension, malignant hypertension, coronary artery disease, cerebrovascular disease, or any surgical or medical condition that might significantly alter the absorption, distribution, metabolism, or excretion of study medications.
The studies were conducted in accordance with Good Clinical Practice, the Declaration of Helsinki of the World Medical Association, and EC Directive 91/507. All of the subjects gave written informed consent. The study protocols were approved by local and central institutional review boards and by the appropriate local research ethics committees.
Study Design
It was planned to recruit 18 to 24 patients to each of the 3 open-label studies. In each, a screening visit was followed by a 7-to 10-day washout period, during which antihypertensive treatment was discontinued. A baseline 24-hour ABPM was then recorded before commencement of study treatments. The screening assessment included a complete medical history, physical examination, clinic blood pressure measurement, safety laboratory tests (blood hematology, blood chemistry, and urinalysis), and 12-lead electrocardiography. At baseline and at the end of each 3-week drug treatment period, adverse events, concurrent medication, and compliance with study medication were recorded, in addition to clinic blood pressure measurement, ABPM, PRA, trough plasma aliskiren levels, safety laboratory tests, and electrocardiography.
Aliskiren/Diuretic Combination Study
All of the patients initially received once-daily oral treatment with aliskiren 150 mg alone for 3 weeks. Only those patients whose daytime ABPM remained Ն135/85 mm Hg had 25 mg of HCTZ once daily added to their treatment regimen for a further 3 weeks. Those patients whose daytime ABPM was Ͻ135/85 mm Hg continued 150 mg of aliskiren alone (Figure 1 ).
ACE Inhibitor/Aliskiren and ARB/Aliskiren Combination Studies
In these 2 studies, patients were initially treated with 5 mg of ramipril once daily or 150 mg of irbesartan daily for 3 weeks. Aliskiren (75 mg) once daily was then added to the ramipril or irbesartan treatment for a further 3-week period. At the end of this second treatment period, the dose of aliskiren was increased to 150 mg daily for the final 3 weeks of both studies (Figure 1 ).
Study Treatments
Throughout the 3 studies, patients were asked to take all of the study medication, once daily, 30 minutes before eating breakfast. Aliskiren was supplied as hard gelatin capsules for oral administration containing 82.88 or 165.75 mg of aliskiren hemifumarate, equivalent to 75 or 150 mg of active aliskiren, respectively. Other study drugs were supplied as commercially available tablets.
Blood Pressure Measurement
Sitting clinic blood pressure measurement and heart rate were measured from the right arm using a regularly calibrated validated automated sphygmomanometer (Omron HEM-705CP). 17 Ambulatory measurements were made every 30 minutes throughout the 24-hour period using SpaceLabs 90207 monitors (SpaceLabs Medical Inc). 18 Mean daytime (9:00 AM and 9:00 PM) and nighttime (1:00 AM and 6:00 AM) systolic and diastolic blood pressures and also heart rates were calculated from ABPMs. ABPM was regarded as satisfactory if there were Ն14 daytime readings and 8 nighttime readings. 19 
Assessment of PRA and Aliskiren Levels
Fasting venous blood was collected from seated patients 24 hours after the last drug intake. PRA was measured by the trapping of generated Ang I by antibodies and by subsequent radioimmunoassay. 20 Aliskiren was measured in 2.5 L of plasma by direct radioimmunoassay with a limit of quantification of 0.15 ng/mL and with intra-assay and inter-assay coefficients of variation Ͻ15%. 14 
Statistical Methods
All of the data analyses were carried out using SAS Software (SAS Institute Inc). Analyses concerning tolerability and safety were conducted on the safety populations, namely all of the patients who received Ն1 dose of study treatment (aliskiren/diuretic combination study: nϭ23; ACE inhibitor/aliskiren combination study: nϭ21; ARB/aliskiren combination study: nϭ23). Analyses concerning drug efficacy were performed on the intention-to-treat population, defined as patients of the safety population who received combination therapy, and who had valid ABPMs at baseline, on monotherapy, and on combination therapy (aliskiren/diuretic combination study: nϭ17; ACE inhibitor/aliskiren combination study: nϭ20; ARB/aliskiren combination study: nϭ21).
For all 3 of the studies, the primary end point was the change in daytime systolic ABPM with combination therapy compared with monotherapy. Mean changes in daytime systolic ABPM were compared using random-effects ANOVA models with Bonferroni's posthoc tests. Similar models were used to analyze treatment effects on secondary end points: daytime diastolic ABPM, nighttime systolic and diastolic ABPM, and daytime and nighttime heart rates. Because PRA values are not normally distributed, these were compared by Kruskal-Wallis tests with Dunn's posthoc tests.
Results
Participants
The distributions of gender, age, body mass index, lifestyle habits, and cardiovascular risk factors among the patients in the 3 studies were similar (Table) . Approximately three fourths of patients in each study were men and between 50 and 60 years old; all of the patients were white. The majority of patients in all 3 of the studies had previously received antihypertensive medication, of which ACE inhibitors and ␤-blockers were the most common agents.
Effect of Aliskiren Monotherapy and Combination Treatment on ABPM
Aliskiren/Diuretic Combination Study At baseline, overall mean daytime systolic ABPM (meanϮSD) was 150.6Ϯ8.9 mm Hg (nϭ23). After 3 weeks of treatment with 150 mg of aliskiren, mean daytime systolic ABPM remained above 135/85 mm Hg in 17 of the 23 patients (142.4Ϯ9.4 mm Hg). HCTZ (25 mg) was added to aliskiren treatment in these patients for 3 weeks, and this led to a significant decrease in mean daytime systolic ABPM to 133.8Ϯ7.0 mm Hg (Pϭ0.0007; nϭ17; Figure 2a and 2b) . The aliskiren/HCTZ combination also significantly lowered daytime diastolic ABPM compared with aliskiren monotherapy (Pϭ0.0006; Figure 2b ). Changes in nighttime systolic and diastolic ABPM followed similar trends but just failed to achieve standard statistical significance (Pϭ0.06 and Pϭ0.09; Figure 2c ). No changes in heart rate were observed (Figure 3a and 3b) . Mean daytime diastolic ABPM was also significantly reduced by the addition of 150 mg of aliskiren to 5 mg of ramipril daily (Figure 3b ), as were nighttime systolic and diastolic ABPM pressures by both aliskiren doses (Figure 3c) . Ramipril alone or in combination with aliskiren had no effect on heart rate.
ARB/Aliskiren Combination Study
Irbesartan monotherapy reduced systolic and diastolic daytime and nighttime ABPM (Figure 4a through 4c ). There was a trend for mean daytime pressures to decrease with the addition of 75 mg of aliskiren, but his trend was not statistically significant ( Figure 4b) . However, the addition of 75 mg of aliskiren to 150 mg of irbesartan did provide significantly greater reductions in nighttime systolic and diastolic ABPM compared with irbesartan monotherapy (PϽ0.05; Figure 4c ). There was a trend for both daytime and nighttime pressures to rise rather than fall when the dose of aliskiren was increased from 75 to 150 mg daily. However, none of these changes was statistically significant. Irbesartan alone or in combination with aliskiren had no effect on heart rate. 
Effect of Aliskiren Alone and in Combination on PRA
In the aliskiren/diuretic combination study, initial treatment with 150 mg of aliskiren alone significantly inhibited PRA by 65% (PϽ0.0001). In the ACE inhibitor/aliskiren and the ARB/aliskiren combination studies, ramipril and irbesartan monotherapy resulted in 90% and 175% increases, respectively, in PRA. By contrast, when aliskiren was coadministered with HCTZ, ramipril, or irbesartan, PRA levels were similar to or less than baseline untreated levels (combination therapy versus untreated: 
Plasma Concentrations of Aliskiren Alone and During Combination Therapy
Aliskiren/Diuretic Combination Study
The mean aliskiren plasma concentration at visit 3, after treatment for 3 weeks with 150 mg of aliskiren, was 
15.0Ϯ10.8 ng/mL (nϭ23)
. No significant differences in the plasma concentrations of aliskiren at week 6 were observed between patients who continued on 150 mg of aliskiren alone (10.7Ϯ6.7 ng/mL) and those who received aliskiren and 25 mg of HCTZ (13.1Ϯ8.3 ng/mL).
Aliskiren/ACE Inhibitor Combination Study
A dose-dependent increase in plasma levels of aliskiren was observed in this study; mean trough plasma concentrations of aliskiren were 3.9Ϯ2.6 ng/mL (nϭ20) after 3 weeks of treatment with 75 mg of ramipril/aliskiren and 9.5Ϯ5.9 ng/mL (nϭ19) after a further 3 weeks of treatment with 150 mg of ramipril/aliskiren.
ARB/Aliskiren Combination Study
Similarly, plasma levels of aliskiren reflected the administered dosage in this study: mean trough plasma concentrations of aliskiren were 3.3Ϯ1.7 ng/mL (nϭ22) after 3 weeks of treatment with 75 mg of irbesartan/aliskiren and 7.6Ϯ3.2 ng/mL (nϭ19) after 3 weeks of treatment with 150 mg of irbesartan/aliskiren.
Compliance, Safety, and Tolerability of Aliskiren Monotherapy and Combination Treatment
Compliance, assessed from counts of returned capsules, averaged Ͼ95% in all of the treatment periods of all 3 studies. Aliskiren was well tolerated either as monotherapy or in combination. A total of 11 adverse events were recorded in 5 patients in the aliskiren/HCTZ study, 25 adverse events in 10 patients in the ramipril/aliskiren study, and 30 adverse events in 17 patients in the irbesartan/aliskiren study (Table I) . Only 2 adverse events were rated as severe: 1 myocardial infarction in a patient receiving irbesartan and 150 mg of aliskiren and headaches in a patient receiving ramipril monotherapy. Overall, there were no clinically significant changes in laboratory parameters at consecutive visits during the course of any of these studies. The maximum individual serum potassium levels recorded when aliskiren was coadministered with ramipril and with irbesartan were 5.3 and 5.5 mmol/L, respectively (see Table II ).
Discussion
The 3 open-label studies reported here investigated whether the antihypertensive effects of aliskiren, a novel, orally effective renin inhibitor, would be increased in combination with a thiazide diuretic and whether aliskiren would provide additional blood pressure lowering in patients with mild-tomoderate hypertension when administered in combination with an ACE inhibitor or with an ARB. Because of the sequential nature of the studies, noninvasive 24-hour ABPM was used to monitor blood pressure, because placebo response and regression to the mean are minimal or absent with this method of blood pressure measurement. 21 Potentiation of the blood pressure-lowering effect of HCTZ by an early generation renin inhibitor, remikiren, had already been demonstrated, but in that study it was notable that remikiren alone exerted no significant antihypertensive effect. 22 By contrast, in our diuretic combination study, monotherapy with 150 mg of aliskiren for 3 weeks significantly lowered daytime systolic ABPM in patients with mild-to-moderate hypertension, and the addition of 25 mg of HCTZ daily to aliskiren treatment led to further significant reductions in daytime systolic and diastolic ABPM. Importantly, the ABPM profiles clearly showed that aliskiren monotherapy and aliskiren in combination with HCTZ provided sustained blood pressure reductions throughout the 24-hour dosing interval. These results likely reflect the long plasma half-life of aliskiren 14 and are consistent with the results of previous studies. 15, 16 Results of a recent preclinical study suggested that aliskiren could potentiate the antihypertensive effects of an ACE inhibitor in spontaneously hypertensive rats. 13 Our article is the first to report the effects of combinations of renin inhibition and downstream RAAS inhibition on blood pressure in humans. The addition of aliskiren to ramipril resulted in significant reductions in both daytime and nighttime systolic and diastolic pressures. Although the addition of aliskiren to irbesartan seemed to lower both daytime and nighttime ABPM, only the nocturnal reductions were statistically significant.
The consistent lowering of nocturnal blood pressures by all 3 of the combination therapies may have particular relevance in view of recent evidence that nocturnal blood pressures predict cardiovascular mortality more powerfully than either clinic or daytime ambulatory pressures. 23 However, it should be noted that submaximal doses of both ramipril and irbesartan were used in these studies. Therefore, any additional blood pressure lowering seen with combination therapy may equally have occurred if the dosage of the ACE inhibitor or the ARB had been increased.
Aliskiren (150 mg), when administered in combination with valsartan (160 mg) to salt-depleted healthy volunteers, has already been reported to suppress the compensatory rise in PRA that would normally be observed during ARB monotherapy. 24 In the current studies, PRA in hypertensive patients taking any of the 3 combinations was either similar to or less than baseline untreated values. The fact that the feedback-induced increase in PRA and Ang I seen with diuretics, ACE inhibitors, and ARBs does not occur during renin inhibition may have potentially favorable consequences. A relationship between PRA and the risk of myocardial infarction in patients with hypertension was first identified by a retrospective analysis conducted Ͼ30 years ago. 25, 26 Recent studies have provided additional evidence that PRA is a predictor of cardiovascular risk. 2, 3 Although these findings are likely to be at least in part because of Ang II-mediated effects, such as increased blood pressure, and effects on atherosclerosis, 27 increased renin or prorenin could also directly increase cardiovascular risk through enhanced stimulation of the newly discovered renin/prorenin receptor, the full effect of which remains to be established. 28 Conversely, there is evidence that Ang-(1-7) contributes to the antihypertensive actions of both ACE inhibitors and ARBs. 29, 30 Renin inhibition would be expected to reduce formation of Ang-(1-7), and, therefore, the addition of renin inhibition to ACE inhibition or ARB could potentially diminish blood pressure lowering. Indeed, the trend for a rise in pressures in the ARB/aliskiren combination study, when the dosage of aliskiren was increased from 75 to 150 mg daily, and the lack of correlation with changes in blood pressure with changes in PRA, suggests that further studies of this combination of agents are certainly warranted, with both greater patient numbers and a wider range of doses. Because a similar phenomenon could also occur when higher doses of aliskiren and an ACE inhibitor are combined, further studies are also advisable.
The good tolerability of aliskiren in these 3 small studies, whether administered alone or in combination with HCTZ, ramipril, or irbesartan, is consistent with other larger studies demonstrating a safety profile for aliskiren equivalent to that of ARBs, 15, 16 a drug class well known for their placebo-like tolerability. A low likelihood of adverse effects would be expected for aliskiren, because renin has a high specificity for its substrate, angiotensinogen. 10 Moreover, renin inhibitors do not affect substance P or kinin metabolism and, hence, would not be expected to cause dry cough or angioneurotic edema, which are characteristic adverse effects of ACE inhibitors. 31 The addition of 25 mg of HCTZ to 150 mg of aliskiren did not seem to alter plasma aliskiren levels. Plasma concentrations of aliskiren administered in combination with ramipril or with irbesartan were similar to those observed after aliskiren monotherapy at doses of 75 and 150 mg in previous studies. 15, 16 These results suggest that it is unlikely that any clinically significant pharmacokinetic interactions occur between aliskiren and HCTZ, between aliskiren and ramipril, or between aliskiren and irbesartan.
Clinical Perspective
The studies reported here show that the novel, orally effective renin inhibitor aliskiren provides 24-hour antihypertensive effects that may be increased by the addition of the diuretic, HCTZ, and that combining aliskiren with the ACE inhibitor, ramipril, or with the ARB, irbesartan, provides significantly greater reductions in blood pressure than with monotherapy. Aliskiren treatment, whether administered alone or in combination with HCTZ, ramipril, or irbesartan, was well tolerated. In addition, aliskiren in combination therapy effectively neutralizes the compensatory rise in PRA that is stimulated by existing antihypertensive agents and, therefore, offers the prospect of optimized RAAS suppression in patients with hypertension. It remains to be seen whether these treatment combinations will provide greater protection from cardiovascular morbidity and mortality.
Sources of Funding
These 3 trials were supported by Speedel Pharma AG, Basel, Switzerland. Java Clinical Research Ltd, Dublin, Ireland, monitored the project.
